Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I&I Target 2
- Development stage
- Preclinical
- Lead developer
- ArrePath
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
I&I Target 2 is an oral small molecule therapeutic candidate being developed by ArrePath (also referred to as RentPath in some pipeline documents) for the treatment of severe asthma. The program is designed to target and control upstream type-2 inflammation, which is a key driver in the pathogenesis of severe asthma. By utilizing ArrePath's proprietary AI/ML-enabled platform, the company aims to discover and optimize oral small molecules against this validated pathway, providing an alternative to existing injectable biologic therapies. The program is currently in the discovery and preclinical stages of development.
Beyond the preview
Go deeper on I&I Target 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on I&I Target 2.